Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F

Nature Communications

Volumn 4, Issue , 2013, Pages

  Siu, Karen K ^a   Sultana, Azmiri ^a   Azimi, Farshad C ^a   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; VIF PROTEIN;

GENETIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INHIBITION; INHIBITOR; MUTAGENICITY; PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING; ENZYME SPECIFICITY; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROMOLECULE; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STATIC ELECTRICITY; VIRUS INFECTIVITY; VIRUS REPLICATION;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYTOSINE DEAMINASE; DNA, SINGLE-STRANDED; ESCHERICHIA COLI; GENE EXPRESSION; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; STATIC ELECTRICITY; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84887276822     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3593     Document Type: Article

References (53)

1. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
2. Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (2003). (Pubitemid 36834849)
3. Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (2003). (Pubitemid 36724943)
4. Jarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296 (2002). (Pubitemid 34211936)
5. LaRue, R. S. et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494-497 (2009).
6. Hultquist, J. F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220-11234 (2011).
7. Dang, Y., Wang, X., Esselman, W. J. & Zheng, Y. H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10522-10533 (2006). (Pubitemid 44628899)
8. Refsland, E. W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274-4284 (2010).
9. Zheng, Y. H. et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076 (2004).
10. Burnett, A. & Spearman, P. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81, 5000-5013 (2007). (Pubitemid 46744412)
11. Conticello, S. G., Harris, R. S. & Neuberger, M. S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013 (2003). (Pubitemid 37425213)
12. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407 (2003). (Pubitemid 37466190)
13. Feng, Y., Love, R. P. & Chelico, L. HIV-1 Vif alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J. Biol. Chem. 288, 6083-6094 (2013).
14. Mercenne, G. et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 38, 633-646 (2010).
15. Stopak, K., De Noronha, C., Yonemoto, W. & Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601 (2003). (Pubitemid 37222482)
16. Smith, J. L. & Pathak, V. K. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84, 12599-12608 (2010).
17. Russell, R. A. & Pathak, V. K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210 (2007). (Pubitemid 47101506)
18. Hache, G., Liddament, M. T. & Harris, R. S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924 (2005). (Pubitemid 40418393)
19. Smith, J. L., Bu, W., Burdick, R. C. & Pathak, V. K. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol. Sci. 30, 638-646 (2009).
20. Byeon, I. J. et al. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat. Commun. 4, 1890 (2013).
21. Chen, K. M. et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119 (2008).
22. Furukawa, A. et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28, 440-451 (2009).
23. Holden, L. G. et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124 (2008).
24. Kitamura, S. et al. The APOBEC3C crystal structure and the interface for HIV- 1 Vif binding. Nat. Struct. Mol. Biol. 19, 1005-1010 (2012).
25. Shandilya, S. M. et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18, 28-38 (2010).
26. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F. & Malim, M. H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5, e1000330 (2009).
27. Bulliard, Y. et al. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83, 12611-12621 (2009).
28. Autore, F., Bergeron, J. R., Malim, M. H., Fraternali, F. & Huthoff, H. Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations. PLoS One 5, e11515 (2010).
29. Krzysiak, T. C., Jung, J., Thompson, J., Baker, D. & Gronenborn, A. M. APOBEC2 is a monomer in solution: implications for APOBEC3G models. Biochemistry 51, 2008-2017 (2012).
30. Liddament, M. T., Brown, W. L., Schumacher, A. J. & Harris, R. S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14, 1385-1391 (2004). (Pubitemid 39081642)
31. Rausch, J. W., Chelico, L., Goodman, M. F. & Le Grice, S. F. Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J. Biol. Chem. 284, 7047-7058 (2009).
32. Gallerano, D. et al. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 40, 981-989 (2011).
33. Dang, Y., Wang, X., Zhou, T., York, I. A. & Zheng, Y. H. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83, 8544-8552 (2009).
34. He, Z., Zhang, W., Chen, G., Xu, R. & Yu, X. F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381, 1000-1011 (2008).
35. Dang, Y., Davis, R. W., York, I. A. & Zheng, Y. H. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84, 5741-5750 (2010).
36. Pery, E., Rajendran, K. S., Brazier, A. J. & Gabuzda, D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83, 2374-2381 (2009).
37. Albin, J. S. et al. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285, 40785-40792 (2010).
38. Yu, Q. et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442 (2004). (Pubitemid 38568947)
39. Langlois, M. A., Beale, R. C., Conticello, S. G. & Neuberger, M. S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33, 1913-1923 (2005). (Pubitemid 41748336)
40. Shih, P., Pedersen, L. G., Gibbs, P. R. & Wolfenden, R. Hydrophobicities of the nucleic acid bases: distribution coefficients from water to cyclohexane. J. Mol. Biol. 280, 421-430 (1998). (Pubitemid 28327280)
41. Huthoff, H. & Malim, M. H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 81, 3807-3815 (2007). (Pubitemid 46586878)
42. Bohn, M. F. et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21, 1042-1050 (2013).
43. D'Arcy, A., Villard, F. & Marsh, M. An automated microseed matrix-screening method for protein crystallization. Acta Crystallogr. D Biol. Crystallogr. 63, 550-554 (2007). (Pubitemid 46465951)
44. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr. D55, 1718-1725 (1999). (Pubitemid 29504426)
45. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007). (Pubitemid 47080256)
46. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D60, 2126-2132 (2004). (Pubitemid 41742764)
47. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
48. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
49. Kelley, L. A. & Sternberg, M. J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 4, 363-371 (2009).
50. Mbisa, J. L., Bu, W. & Pathak, V. K. APOBEC3F and APOBEC3G inhibit HIV- 1 DNA integration by different mechanisms. J. Virol. 84, 5250-5259 (2010).
51. Goujon, M. et al. A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res. 38, W695-W699 (2010).
52. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (2007). (Pubitemid 350162903)
53. Gouet, P. & Courcelle, E. ENDscript: a workflow to display sequence and structure information. Bioinformatics 18, 767-768 (2002). (Pubitemid 34679126)